MEI Pharma and Kyowa Kirin Report Clinical Data on Zandelisib at European Hematology Association 2022 Hybrid Congress
– Zandelisib Demonstrated 70.3% Objective Response Rate and 35.2% Complete Response Rate – – 87.5% of Responses Achieved in First Two Cycles of Therapy, 75% of Complete Responses in first four cycles – – 9.9% of Patients Discontinued Therapy Due to a Drug Related Adverse Event – – Primarily, Grade 3 AESIs to Date Occurred … [Read more…]